BMRA Quote, Financials, Valuation and Earnings

Retractable Technologies has a net margin of -58.07% compared to Biomerica's net margin of -18.58%. Biomerica's return on equity of -81.84% beat Retractable Technologies's return on equity of -16.83%.

Biomerica has a consensus price target of --, signalling upside risk potential of 1834.52%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Biomerica has higher upside potential than Retractable Technologies, analysts believe Biomerica is more attractive than Retractable Technologies.

Biomerica has a beta of -1.163, which suggesting that the stock is 216.324% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.083, suggesting its more volatile than the S&P 500 by 108.265%.

Biomerica has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomerica pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

Biomerica quarterly revenues are $1.6M, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Biomerica's net income of -$950K is higher than Retractable Technologies's net income of -$1.9M. Notably, Biomerica's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomerica is 2.04x versus 0.59x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -58.07% compared to Biomerica's net margin of -1226.82%. Biomerica's return on equity of -81.84% beat VolitionRX's return on equity of --.

Biomerica has a consensus price target of --, signalling upside risk potential of 1834.52%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 513.33%. Given that Biomerica has higher upside potential than VolitionRX, analysts believe Biomerica is more attractive than VolitionRX.

Biomerica has a beta of -1.163, which suggesting that the stock is 216.324% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

Biomerica has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomerica pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Biomerica quarterly revenues are $1.6M, which are larger than VolitionRX quarterly revenues of $474.5K. Biomerica's net income of -$950K is higher than VolitionRX's net income of -$5.8M. Notably, Biomerica's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomerica is 2.04x versus 35.50x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -58.07% compared to Biomerica's net margin of -4291.67%. Biomerica's return on equity of -81.84% beat Catheter Precision's return on equity of -65.84%.

Biomerica has a consensus price target of --, signalling upside risk potential of 1834.52%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 376.19%. Given that Biomerica has higher upside potential than Catheter Precision, analysts believe Biomerica is more attractive than Catheter Precision.

Biomerica has a beta of -1.163, which suggesting that the stock is 216.324% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.541, suggesting its less volatile than the S&P 500 by 154.132%.

Biomerica has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomerica pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Biomerica quarterly revenues are $1.6M, which are larger than Catheter Precision quarterly revenues of $96K. Biomerica's net income of -$950K is higher than Catheter Precision's net income of -$4.1M. Notably, Biomerica's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomerica is 2.04x versus 1.12x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -58.07% compared to Biomerica's net margin of -10.04%. Biomerica's return on equity of -81.84% beat Xtant Medical Holdings's return on equity of -35.34%.

Biomerica has a consensus price target of --, signalling upside risk potential of 1834.52%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 224.07%. Given that Biomerica has higher upside potential than Xtant Medical Holdings, analysts believe Biomerica is more attractive than Xtant Medical Holdings.

Biomerica has a beta of -1.163, which suggesting that the stock is 216.324% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

Biomerica has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomerica pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Biomerica quarterly revenues are $1.6M, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Biomerica's net income of -$950K is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Biomerica's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomerica is 2.04x versus 0.62x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.